Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)

To assess the efficacy and safety of TY-9591 versus Osimertinib in patients with locally advanced or Metastatic Non Small Cell Lung Cancer.

Trial Details

NCT ID
NCT05382728
Phase
PHASE3
Sponsor
TYK Medicines, Inc
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • TY-9591
  • placebo Osimertinib
  • Osimertinib
  • placebo TY-9591
Locations (sample)
  • Changsha, Hunan, China|28.19874,112.97087
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Male or female aged ≥18 years and \<80 years.
  • Locally advanced or metastatic NSCLC diagnosed by histology or cytology.
  • Presence of an activating EGFR-sensitive mutations (including exon 19 deletions, L858R, the above mentioned mutations alone or co-existed with othe…
  • No prior systemic antitumor therapy for locally advanced or metastatic NSCLC.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →